Listed

IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2013

Filed with the SEC on Nov 8, 2013 and accepted by EDGAR at Nov 8, 2013, 17:25 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-07-01 to 2013-09-30$1.1mus-gaap:Revenues
Revenue6 months2013-04-01 to 2013-09-30$2.3mus-gaap:Revenues
Cost of revenue3 months2013-07-01 to 2013-09-30$943.5kus-gaap:CostOfRevenue
Cost of revenue6 months2013-04-01 to 2013-09-30$1.9mus-gaap:CostOfRevenue
Selling, general and administrative3 months2013-07-01 to 2013-09-30$475.0kus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2013-04-01 to 2013-09-30$774.1kus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2013-07-01 to 2013-09-30−$432.7kus-gaap:OperatingIncomeLoss
Operating income6 months2013-04-01 to 2013-09-30−$693.5kus-gaap:OperatingIncomeLoss
Interest expense3 months2013-07-01 to 2013-09-30$68.8kus-gaap:InterestExpense
Interest expense6 months2013-04-01 to 2013-09-30$181.0kus-gaap:InterestExpense
Income tax3 months2013-07-01 to 2013-09-30$1.5kus-gaap:IncomeTaxExpenseBenefit
Income tax6 months2013-04-01 to 2013-09-30$3.1kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2013-07-01 to 2013-09-30−$615.2kus-gaap:NetIncomeLoss
Net income6 months2013-04-01 to 2013-09-30−$1.2mus-gaap:NetIncomeLoss
Diluted EPS3 months2013-07-01 to 2013-09-30−$0.09us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2013-04-01 to 2013-09-30−$0.18us-gaap:EarningsPerShareDiluted
Basic EPS3 months2013-07-01 to 2013-09-30−$0.09us-gaap:EarningsPerShareBasic
Basic EPS6 months2013-04-01 to 2013-09-30−$0.18us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2013-07-01 to 2013-09-307,116,180 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2013-04-01 to 2013-09-307,116,180 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2013-04-01 to 2013-09-30−$415.8kus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2013-09-30$726.8kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-09-30$3.9mus-gaap:AssetsCurrent
Total assetsAt period end2013-09-30$18.5mus-gaap:Assets
Current liabilitiesAt period end2013-09-30$3.4mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-09-30$4.1mus-gaap:Liabilities
Short-term borrowingsAt period end2013-09-30$0us-gaap:ShortTermBorrowings
Shareholders' equityAt period end2013-09-30$13.9mus-gaap:StockholdersEquity
Shares outstandingAt period end2013-09-307,481,426 sharesdei:EntityCommonStockSharesOutstanding

Source: SEC EDGAR, the filing index for accession 0001185185-13-002348. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.